Day Return
YTD Return
1-Year Return
3-Year Return
5-Year Return
Note: Sector performance is calculated based on the previous closing price of all sector constituents
Industries in This Sector
Select an Industry for a Visual Breakdown
| Industry | Market Weight | YTD Return | |
|---|---|---|---|
| All Industries | 100.00% | 6.85% | |
| Drug Manufacturers - General | 32.93% | 8.97% | |
| Healthcare Plans | 13.51% | 0.61% | |
| Medical Devices | 12.74% | 7.18% | |
| Biotechnology | 11.53% | 0.41% | |
| Diagnostics & Research | 10.70% | 0.08% | |
| Medical Instruments & Supplies | 7.80% | 25.80% | |
| Medical Care Facilities | 2.94% | 15.88% | |
| Drug Manufacturers - Specialty & Generic | 2.81% | 0.36% | |
| Medical Distribution | 2.52% | 20.29% | |
| Health Information Services | 2.39% | 25.73% | |
| Pharmaceutical Retailers | 0.12% | -63.95% | |
Note: Percentage % data on heatmap indicates Day Return
All Industries
--
<= -3
-2
-1
0
1
2
>= 3
Largest Companies in This Sector
View MoreName | Last Price | 1Y Target Est. | Market Weight | Market Cap | Day Change % | YTD Return | Avg. Analyst Rating |
|---|---|---|---|---|---|---|---|
| 788.19 | 999.43 | 10.66% | | | | Buy | |
| 608.38 | 625.10 | 8.42% | | | | Buy | |
| 155.40 | 175.98 | 5.63% | | | | Buy | |
| 183.08 | 208.90 | 4.87% | | | | Buy | |
| 103.12 | 133.43 | 3.92% | | | | Buy | |
| 118.95 | 130.24 | 3.10% | | | | Buy | |
| 521.66 | 657.43 | 3.00% | | | | Buy | |
| 538.55 | 539.24 | 2.88% | | | | Buy | |
| 238.83 | 288.34 | 2.59% | | | | Buy | |
| 280.07 | 335.10 | 2.26% | | | | Buy |
Investing in the Healthcare Sector
Start Investing in the Healthcare Sector Through These ETFs and Mutual Funds
ETF Opportunities
View MoreName | Last Price | Net Assets | Expense Ratio | YTD Return |
|---|---|---|---|---|
| 146.95 | 39.816B | 0.09% | | |
| 271.38 | 20.549B | 0.10% | | |
| 100.00 | 7.244B | 0.35% | | |
| 141.59 | 7.086B | 0.45% | | |
| 60.95 | 4.783B | 0.40% | |
Mutual Fund Opportunities
View MoreName | Last Price | Net Assets | Expense Ratio | YTD Return |
|---|---|---|---|---|
| 213.40 | 45.697B | 0.30% | | |
| 90.01 | 45.697B | 0.30% | | |
| 135.77 | 20.549B | 0.10% | | |
| 96.93 | 14.589B | 0.80% | | |
| 96.57 | 14.589B | 0.80% | |
Healthcare Research
View MoreDiscover the Latest Analyst and Technical Research for This Sector
Analyst Report: Solventum Corp
Solventum has four business segments: MedSurg, Dental Solutions, Health Information Systems and Purification and Filtration. Solventum's MedSurg segment provides advanced wound care and surgical solutions. Customers include public and private health systems, ambulatory surgical centers, skilled nursing facilities and long-term care facilities. The addressable market for the company in this segment is approximately $26 billion and is growing at a 3%-5% rate. MedSurg's revenue has been flat over the past three years, with an average operating margin of approximately 23%. Solventum's Dental Solutions is a provider of a comprehensive suite of restorative, prevention and orthodontic solutions for dentists and orthodontists. The addressable market for the company in this segment is approximately $17 billion and is growing at a 4%-6% rate. Dental Solutions revenue has declined 5% over the past three years, and the average operating margin has been approximately 33%. Solventum's Health Information Systems (HIS) segment provides software solutions powered by clinical intelligence that create time for clinicians to care for patients and improve accuracy in healthcare reimbursement. Target customer markets include public and private hospitals, physician groups and clinics, federal government agencies and payer organizations. The addressable market for the company in this segment is approximately $9 billion and is growing at a 6%-8% rate. HIS revenue has risen 10% over the past three years, and the average operating margin has been approximately 31%. Solventum's Purification and Filtration segment provides filters and membranes for use in the manufacturing of biopharmaceutical and medical technologies, microelectronics and food and beverage products, as well as filtration for cleaner drinking water. Clients include biopharmaceutical and medical device manufacturers. The addressable market for the company in this segment is approximately $41 billion and is growing at a 4%-6% rate. PF revenue has declined 3% over the past three years, and the average operating margin has been approximately 18%. The company has 22,000 employees. SOLV is a component of the S&P 500 Index.
RatingPrice TargetDaily – Vickers Top Insider Picks for 11/27/2024
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Buyers & Sellers for 11/27/2024
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Market Digest: ADI, CCEP, WBD, SOLV
As we approach the end of 2024, one might suspect that institutions, hedge funds, and money managers that are beating their benchmark might lighten up on their equity exposure and start planning for 2025. Meanwhile, those that manage money and are behind going into December have little time to catch up -- and might be inclined to grab some of the highest momentum stocks out there and increase their risk exposure. But December can be difficult to navigate, as what appears likely to happen doesn't always play out as expected. Looking for the largest stocks in the S&P 500 (SPX) that have done the best over the past month, we note Amazon (AMZN +11%), Tesla (TSLA +26%), Walmart (WMT +11%), JPMorgan (JPM +13%), Visa (V +11%), UnitedHealth (UNH +8%), Oracle (ORCL +10%), Costco (COST +9%), Netflix (NFLX +16%), Bank of America (BAC +14%), and Salesforce (CRM +18%). The market cap of these companies ranges from $330 billion to $3.5 trillion. The list is dominated by Consumer Discretionary and Financial, which just happen to be the hottest sectors from the past month. The S&P 500 finished at an all-time high (ATH) on Tuesday, finishing above 6,000 after a 0.6% pop. There is no chart resistance or overhead supply when an index or stock is in ATH territory. To come up with potential resistance, we must rely on trendlines and Fibonacci (FIBO) extensions based on the size of the last completed base (formed from July to September). Looking out a month, trendline resistance and a 100% FIBO extension sit up at about 6,200. Other FIBO extensions come in at 6,350 and 6,540.



















